- Conditions
- Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastroesophageal Adenocarcinoma
- Interventions
- MLN8237 (Alisertib)
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Houston, Texas • Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- Cytarabine, Idarubicin, Alisertib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- HR+/HER2+ Breast Cancer, Metastatic Breast Cancer
- Interventions
- Alisertib
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Estrogen Receptor Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- Alisertib, Fulvestrant, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lung Cancer, Mesothelioma
- Interventions
- Alisertib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
- Interventions
- alisertib, methotrexate, cisplatin, carboplatin, cyclophosphamide, etoposide, topotecan, vincristine, Surgical resection, Radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 9
- States / cities
- Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Alisertib
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 30
- States / cities
- Daphne, Alabama • Long Beach, California • Lone Tree, Colorado + 24 more
- Conditions
- Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
- Interventions
- Alisertib, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 50
- States / cities
- Hartford, Connecticut • New Britain, Connecticut • Orlando, Florida + 37 more
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
- Interventions
- alisertib, rituximab, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Columbus, Ohio
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
- Interventions
- Alisertib, Bortezomib, Laboratory Biomarker Analysis, Rituximab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 4
- States / cities
- New York, New York • The Bronx, New York • Philadelphia, Pennsylvania
- Conditions
- Advanced Solid Tumors
- Interventions
- Alisertib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Ovarian Carcinoma
- Interventions
- Alisertib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Berkeley Heights, New Jersey
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- Alisertib, Abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Kidney Neoplasm, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
- Interventions
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more
- Conditions
- Advanced Solid Tumors, Adenocarcinoma of the Prostate
- Interventions
- Alisertib, Docetaxel
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Portland, Oregon • San Antonio, Texas + 1 more
- Conditions
- Metastatic Breast Cancer, Solid Tumors
- Interventions
- Alisertib, MLN0128
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Advanced Solid Tumors, Relapsed/Refractory Lymphoma
- Interventions
- Alisertib, Itraconazole
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • Oklahoma City, Oklahoma • Germantown, Tennessee + 1 more
- Conditions
- Acute Myelogenous Leukemia, High-Grade Myelodysplastic Syndrome
- Interventions
- Alisertib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Morristown, New Jersey
- Conditions
- Head and Neck Cancer
- Interventions
- MLN8237, Cetuximab, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Melanoma, Stage IIIc Melanoma, Stage IV Melanoma
- Interventions
- laboratory biomarker identification and analysis, biopsy, immunohistochemistry/tissue microarrays, TdT-mediated dUTP nick end labeling assay, mass spectrometry
- Other · Procedure · Genetic
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
- Interventions
- MLN1117, TAK-659, Alisertib, Paclitaxel, Docetaxel
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Lake Success, New York • New York, New York • Philadelphia, Pennsylvania + 2 more
- Conditions
- CD30-positive Lymphoma, CD30-positive Solid Tumor
- Interventions
- Brentuximab Vedotin, Alsertib
- Drug
- Lead sponsor
- Eric Bernicker, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- Alisertib, Fulvestrant, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
- Conditions
- Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma
- Interventions
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 160
- States / cities
- Mobile, Alabama • Tucson, Arizona • Berkeley, California + 107 more